SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Downtown San Francisco and Oakland Bay Bridge on sunny day
Job Trends
Life Sciences Employment Growth in California Slows—and Could Keep Slowing
California’s life sciences jobs led the nation last year, according to a new California Life Sciences (CLS) report. However, employment growth slowed and could continue slowing. CLS President and CEO Mike Guerra discusses the critical factors influencing California’s success.
June 20, 2025
 · 
4 min read
 · 
Angela Gabriel
Business
Navigating Funding Freezes and AI Frontiers
In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis discusses key themes from BIO and DIA, including the funding environment, with Rich Daly, CEO of Catalyst Pharmaceuticals, Peter Ronco, CEO of Emmes Corporation, and Phil Vanek, founder of Redline Bio Advisors.
June 20, 2025
 · 
1 min read
 · 
Lori Ellis
Vaccines
Quick on Its Feet: Novavax Adapts to Continued Regulatory Uncertainty
After the delayed approval of its next-generation COVID-19 vaccine, Novavax now awaits the first meeting of the recently overhauled CDC vaccine advisory committee next week. Throughout a tumultuous season, the Maryland-based company is relying on agility and a diverse pipeline to stay ahead of rapidly changing regulations.
June 20, 2025
 · 
3 min read
 · 
Heather McKenzie
A woman speaking into a microphone while standing behind a lectern
Government
Nicole Verdun Exits FDA as CBER Director Vinay Prasad ‘Consolidates Power’
The well-respected director of the FDA’s cell and gene therapy office was seen as a stabilizing and trustworthy voice inside the quickly reshaping FDA, especially since the late-March exit of CBER Director Peter Marks.
June 20, 2025
 · 
3 min read
 · 
Dan Samorodnitsky
Gilead's headquarters in Silicon Valley
FDA
Gilead Wins Historic Approval for Twice-Yearly HIV Drug
Lenacapavir, to be marketed as Yeztugo, could “redefine the PReP market,” according to analysts.
June 18, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Contemporary art collage. employee mowing forward to success, stepping ladder of professional growth. Concept of business.
Obesity
Scholar Rock Jumps on Weight Loss Data for Zepbound/Repurposed Antibody Combo
In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped patients lose the same amount of weight as patients on tirzepatide alone while preserving more muscle mass.
June 18, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Pictured: Eli Lilly Campus in San Diego
Business
More Than a One Trick Pony, Lilly Feeds Success Back Into Biotech
On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the company is leveraging its unprecedented success in obesity to support young biotechs.
June 18, 2025
 · 
3 min read
 · 
Heather McKenzie
Creative photo poster picture collage collapsing dollar banknote arm holding cash money bankrupt decrease income funds loss.
Venture capitalists
More Than One-Third of Biotechs Have Under a Year of Cash Left, EY Finds
EY’s 2025 Biotech Beyond Borders report provides a sobering snapshot of the industry’s financial health, with more and more companies facing cash runways of less than one year. The analyst firm’s leaders urge a return to basics for biotech.
June 18, 2025
 · 
4 min read
 · 
Ana Mulero
A man is holding an umbrella while standing on a cliff. The umbrella is green and the man is looking up at the sky. Concept of danger and uncertainty, as the man is on the edge of a cliff
Regulatory
FDA Chief’s New Voucher Program Could Ease Biotech Investors’ Anxiety
Industry watchers responded mostly positively to the commissioner’s new voucher program, but worries remain over staffing cuts at the agency.
June 18, 2025
 · 
2 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS